Amphastar Pharmaceuticals (NASDAQ:AMPH) Receives New Coverage from Analysts at Bank of America

Bank of America started coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research report released on Friday, Marketbeat.com reports. The brokerage issued a neutral rating and a $63.00 price objective on the stock.

A number of other research firms also recently weighed in on AMPH. Jefferies Financial Group began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They set a buy rating and a $70.00 target price for the company. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, November 13th. Finally, Piper Sandler increased their target price on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research note on Wednesday, August 9th.

Amphastar Pharmaceuticals Trading Up 1.3 %

Shares of AMPH stock opened at $56.59 on Friday. Amphastar Pharmaceuticals has a 52-week low of $27.58 and a 52-week high of $67.66. The company has a 50-day simple moving average of $47.51 and a two-hundred day simple moving average of $50.81. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of 22.11 and a beta of 0.87. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.68 and a current ratio of 2.11.

Insider Activity

In other news, CFO William J. Peters sold 60,743 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the sale, the chief financial officer now owns 101,360 shares in the company, valued at approximately $5,245,380. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CFO William J. Peters sold 60,743 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the transaction, the chief financial officer now owns 101,360 shares of the company’s stock, valued at approximately $5,245,380. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard K. Prins sold 4,000 shares of the stock in a transaction on Friday, November 17th. The shares were sold at an average price of $55.86, for a total transaction of $223,440.00. Following the transaction, the director now directly owns 31,895 shares in the company, valued at approximately $1,781,654.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 99,559 shares of company stock worth $5,205,924. 28.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. West Tower Group LLC bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth $39,000. Point72 Middle East FZE purchased a new position in Amphastar Pharmaceuticals during the 4th quarter valued at about $50,000. Ronald Blue Trust Inc. raised its holdings in Amphastar Pharmaceuticals by 821.5% in the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after buying an additional 1,068 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after buying an additional 628 shares during the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Amphastar Pharmaceuticals in the second quarter worth about $59,000. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).